{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:23:10Z","timestamp":1757456590882},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the relative efficacy of intravenous golimumab (GOL IV) and infliximab (IFX) for active ankylosing spondylitis (AS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Propensity score\u00a0(PS) methods\u00a0were used to compare the efficacy of GOL IV 2\u00a0mg\/kg and IFX 5\u00a0mg\/kg using individual patient data (IPD) from the active arms of the phase 3 GO-ALIVE and ASSERT studies. Outcomes included the proportion of patients with a \u2265\u200920% improvement in the Assessment of Spondyloarthritis International Society Criteria (ASAS20), change from baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) score, and change from baseline in C-reactive protein (CRP) levels from weeks 4\u201352.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Before matching, 105 patients were treated with GOL IV and 201 patients were treated with IFX. After matching on all covariates, 118 patients were included in the ASAS20 analysis, 96 in the BASFI analysis, and 160 in the CRP analysis. After matching, GOL IV showed significantly greater improvement in ASAS20 response than IFX for weeks 28\u201344 (e.g., OR\u2009=\u20099.05 [95% CI 1.62\u201350.4] at week 44) and was comparable in change from baseline in BASFI scores and CRP levels to IFX at all time points. Results were robust for inclusion of different sets of covariates in scenario analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first analysis of its kind to leverage clinical trial data to compare two biologics using PS\u00a0methods in the treatment of active AS. Overall, GOL IV was associated with greater improvement in ASAS20 response than IFX in patients with AS at 28, 36, and 44\u00a0weeks of follow-up.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Although intravenous golimumab (GOL IV) and infliximab (IFX) are the only two IV-based tumor necrosis factor (TNF) inhibitors with demonstrated phase 3 clinical efficacy in patients with ankylosing spondylitis (AS), no study has evaluated their comparative efficacy in a head-to-head trial.<\/jats:italic><jats:italic>\u2022 Propensity score matching was used to derive indirect treatment comparisons of GOL IV and IFX for \u2265\u200920% in the Assessment of Spondyloarthritis International Society Criteria (ASAS20), change in Bath Ankylosing Spondylitis Functional Index (BASFI), and change in C-reactive protein (CRP) using individual patient data from the GO-ALIVE and ASSERT phase 3 trials.<\/jats:italic><jats:italic>\u2022 Propensity score matched indirect comparisons showed improved relative efficacy of GOL IV compared to IFX; after matching for up to 16 baseline covariates, GOL IV was associated with significantly greater odds of ASAS20 response at weeks 28, 36, and 44 than IFX as well as equivalent changes from baseline in BASFI and CRP.<\/jats:italic><jats:italic>\u2022 This novel application of propensity score matching using data from phase 3 trials, the first analysis of its kind in AS, allowed adjustment for important imbalances in prognostic factors between trials to generate estimates of comparative efficacy between GOL IV and IFX in the absence of a head-to-head trial between these treatments.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-020-05051-1","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T20:02:36Z","timestamp":1588622556000},"page":"2907-2917","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Propensity score matching\/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials"],"prefix":"10.1007","volume":"39","author":[{"given":"L. S.","family":"Gensler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Spin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"issue":"18","key":"5051_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa012664","journal-title":"N Engl J Med"},{"key":"5051_CR2","doi-asserted-by":"publisher","unstructured":"Garcia-Montoya L, Gul H, Emery P (2018) Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res 7. https:\/\/doi.org\/10.12688\/f1000research.14956.1","DOI":"10.12688\/f1000research.14956.1"},{"issue":"2","key":"5051_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 68(2):282\u2013298. https:\/\/doi.org\/10.1002\/art.39298","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5051_CR4","first-page":"613","volume":"27","author":"A Zink","year":"2000","unstructured":"Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613\u2013622","journal-title":"J Rheumatol"},{"issue":"7","key":"5051_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/rheumatology\/36.7.766","volume":"36","author":"JT Gran","year":"1997","unstructured":"Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36(7):766\u2013771","journal-title":"Br J Rheumatol"},{"issue":"4","key":"5051_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H","volume":"12","author":"MM Ward","year":"1999","unstructured":"Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247\u2013255","journal-title":"Arthritis Care Res"},{"issue":"6","key":"5051_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/1529-0131(199806)41:6<1119::Aid-art20>3.0.Co;2-0","volume":"41","author":"AL Taylor","year":"1998","unstructured":"Taylor AL, Balakrishnan C, Calin A (1998) Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 41(6):1119\u20131125. https:\/\/doi.org\/10.1002\/1529-0131(199806)41:6<1119::Aid-art20>3.0.Co;2-0","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5051_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003060","volume":"95","author":"C Chen","year":"2016","unstructured":"Chen C, Zhang X, Xiao L, Zhang X, Ma X (2016) Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore) 95(11):e3060. https:\/\/doi.org\/10.1097\/MD.0000000000003060","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"5051_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford) 53(9):1654\u20131663. https:\/\/doi.org\/10.1093\/rheumatology\/keu132","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5051_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, G\u00e9her P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Comp\u00e0n V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"9906","key":"5051_CR11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/s0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 382(9906):1705\u20131713. https:\/\/doi.org\/10.1016\/s0140-6736(13)61134-4","journal-title":"Lancet (London, England)"},{"issue":"9999","key":"5051_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/s0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewe R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 386(9999):1137\u20131146. https:\/\/doi.org\/10.1016\/s0140-6736(15)61134-5","journal-title":"Lancet (London, England)"},{"issue":"4","key":"5051_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Jarvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD (2019) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase iii randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol 71(4):599\u2013611. https:\/\/doi.org\/10.1002\/art.40753","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"5051_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. https:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"issue":"9313","key":"5051_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (London, England) 359(9313):1187\u20131193","journal-title":"Lancet (London, England)"},{"issue":"6","key":"5051_CR16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::Aid-anr18>3.0.Co;2-e","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346\u20131352. https:\/\/doi.org\/10.1002\/1529-0131(200006)43:6<1346::Aid-anr18>3.0.Co;2-e","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5051_CR17","first-page":"163","volume":"1","author":"R Grainger","year":"2007","unstructured":"Grainger R, Harrison AA (2007) Infliximab in the treatment of ankylosing spondylitis. Biologics 1(2):163\u2013171","journal-title":"Biologics"},{"issue":"3","key":"5051_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","volume":"45","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2018) Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45(3):341\u2013348. https:\/\/doi.org\/10.3899\/jrheum.170487","journal-title":"J Rheumatol"},{"key":"5051_CR19","unstructured":"Janssen Biotech Inc (2018) Medication Guide: Simponi Aria. Last updated: May, 2018. Last accessed: January 17, 2019"},{"issue":"3","key":"5051_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"issue":"1","key":"5051_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci 25(1):1\u201321. https:\/\/doi.org\/10.1214\/09-STS313","journal-title":"Stat Sci"},{"issue":"4","key":"5051_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-017-0611-3","volume":"38","author":"H Mann","year":"2018","unstructured":"Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C (2018) Adjusted indirect comparison using propensity score matching of osimertinib to platinum-based doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI. Clin Drug Investig 38(4):319\u2013331. https:\/\/doi.org\/10.1007\/s40261-017-0611-3","journal-title":"Clin Drug Investig"},{"issue":"4","key":"5051_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5051_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10(2):150\u2013161. https:\/\/doi.org\/10.1002\/pst.433","journal-title":"Pharm Stat"},{"issue":"25","key":"5051_CR25","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"issue":"8 Suppl","key":"5051_CR26","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","volume":"66","author":"EA Stuart","year":"2013","unstructured":"Stuart EA, Lee BK, Leacy FP (2013) Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol 66(8 Suppl):S84\u2013S90.e81. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.01.013","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"5051_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.20790","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, Hallegua DS, Bruckel J (2005) ASsessment in Ankylosing Spondylitis International Working Group\/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 52(2):386\u2013394. https:\/\/doi.org\/10.1002\/art.20790","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5051_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"R Landewe","year":"2015","unstructured":"Landewe R, van Tubergen A (2015) Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep 17(7):47. https:\/\/doi.org\/10.1007\/s11926-015-0522-3","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"5051_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","volume":"49","author":"M Benhamou","year":"2009","unstructured":"Benhamou M, Gossec L, Dougados M (2009) Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on C-reactive protein. Rheumatology 49(3):536\u2013541. https:\/\/doi.org\/10.1093\/rheumatology\/kep393","journal-title":"Rheumatology"},{"key":"5051_CR30","doi-asserted-by":"publisher","unstructured":"Deodhar A, Chakravarty SD, Cameron C, Peterson S, Hensman R, Fogarty S, Spin P, Kafka S, Nair S, Gensler LS (2020). A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-04970-3","DOI":"10.1007\/s10067-020-04970-3"},{"issue":"4","key":"5051_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3899\/jrheum.170224","volume":"45","author":"R Wang","year":"2018","unstructured":"Wang R, Dasgupta A, Ward MM (2018) Comparative efficacy of tumor necrosis factor-alpha inhibitors in ankylosing spondylitis: a systematic review and Bayesian network metaanalysis. J Rheumatol 45(4):481\u2013490. https:\/\/doi.org\/10.3899\/jrheum.170224","journal-title":"J Rheumatol"},{"key":"5051_CR32","unstructured":"R Core Team (2013) R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. Available at: Http:\/\/www.R-project.Org\/. Accessed 1 Dec 2018"},{"issue":"9","key":"5051_CR33","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3899\/jrheum.151244","volume":"43","author":"MJ Kviatkovsky","year":"2016","unstructured":"Kviatkovsky MJ, Ramiro S, Landewe R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martin-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D (2016) The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol 43(9):1680\u20131686. https:\/\/doi.org\/10.3899\/jrheum.151244","journal-title":"J Rheumatol"},{"key":"5051_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev.publhealth.21.1.121","volume":"21","author":"RJ Little","year":"2000","unstructured":"Little RJ, Rubin DB (2000) Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 21:121\u2013145. https:\/\/doi.org\/10.1146\/annurev.publhealth.21.1.121","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"5051_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40261-014-0246-6","volume":"35","author":"A Migliore","year":"2015","unstructured":"Migliore A, Bizzi E, Bernardi M, Picchianti Diamanti A, Lagana B, Petrella L (2015) Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clinical drug investigation 35(1):23\u201329. https:\/\/doi.org\/10.1007\/s40261-014-0246-6","journal-title":"Clinical drug investigation"},{"issue":"5","key":"5051_CR36","first-page":"717","volume":"31","author":"T Shu","year":"2013","unstructured":"Shu T, Chen GH, Rong L, Feng F, Yang B, Chen R, Wang J (2013) Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol 31(5):717\u2013722","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"5051_CR37","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1007\/s10198-014-0593-5","volume":"15","author":"P Baji","year":"2014","unstructured":"Baji P, Pentek M, Szanto S, Geher P, Gulacsi L, Balogh O, Brodszky V (2014) Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ 15(Suppl 1):S45\u2013S52. https:\/\/doi.org\/10.1007\/s10198-014-0593-5","journal-title":"Eur J Health Econ"},{"key":"5051_CR38","doi-asserted-by":"publisher","first-page":"32768","DOI":"10.1038\/srep32768","volume":"6","author":"W Liu","year":"2016","unstructured":"Liu W, Wu YH, Zhang L, Liu XY, Bin X, Bin L, Wang Y, Ji Y (2016) Efficacy and safety of TNF-alpha inhibitors for active ankylosing spondylitis patients: multiple treatment comparisons in a network meta-analysis. Sci Rep 6:32768. https:\/\/doi.org\/10.1038\/srep32768","journal-title":"Sci Rep"},{"issue":"6","key":"5051_CR39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ (2012) Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6):940\u2013947. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004","journal-title":"Value Health"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05051-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:27:34Z","timestamp":1620088054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05051-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5051"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05051-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Cornerstone received financial support from Janssen Scientific Affairs, LLC, for the conduct of this study. S.D. Chakravarty, S. Peterson, and S. Kafka are employees and shareholders of Johnson and Johnson. S. Nair is an employee of Johnson and Johnson. C. Cameron is an employee and shareholder of EVERSANA\u2122. P. Spin is an employee of EVERSANA\u2122. EVERSANA\u2122 consults for various pharmaceutical, medical device, and biotech companies.AD has received research grants and\/or has served on the advisory boards of AbbVie, Amgen, Boeheringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galxo Smith & Klien, Janssen, Novartis, Pfizer and UCB.LSG has received research grants and\/or has served on the advisory boards of AbbVie, Amgen, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}